SECFilings.com published an article covering the ophthalmology segment and Axim Biotechnologies Inc (OTCMKTS:AXIM) cannabinoid-based therapies. International ophthalmology revenue is expected to grow at a compound annual growth rate of 9.48% to $26 billion by 2022 from $13.7 billion in 2015, according to Research and Markets. Irrespective of medical advances, most ophthalmic problems cannot be cured and treatment is intended at managing the disease indication to lower the severity of indications and reduce the advancement of visual field loss over time.
AXIM Biotechnologies considers that cannabinoids could play a vital role in managing ophthalmology indications and probably even reversing some ailments. With two plans in its clinical pipeline, the firm is targeting dry eye and glaucoma, two of the most widespread ophthalmological problems. The concept that cannabinoids can be useful in treating glaucoma goes back to the 1970s.
Trials performed then demonstrated that smoking marijuana lowered IOP in people with glaucoma, however the effects only remained for just three or four hours. In addition, smoking pot resulted in a drop in blood pressure that may result in a harmful decline in blood flow to the already-weak optic nerve.
In 2000, researchers advanced a non-psychotropic synthetic cannabinoid named as HU-211, and identified that a single dose lowered IOP by 5.3 mmHg in rabbits over a 6-hour period. Since the Hemp was given locally, there was no systemic decline in blood pressure that would have led the optic nerve at risk. This data demonstrated that non-whole-plant or synthetic cannabinoids could play a vital role in ophthalmology.
Researchers have considered these findings and other innovations and used them to grow into other segments of ophthalmology, ranging from inflammatory ailments of the eye to the problem of dry eye. Google Scholar lists around 600 papers issued this year alone covering the words “ophthalmology” and “cannabinoid”, which suggests a grown interest in the segment. Axim Biotechnologies has joined these positions with at least two clinical plans in process.